Abstract:Objective: The study aims to analyze the clinical characteristics of acute phase of SARS-CoV-2 infection in children aged 0–17 years with the Omicron variant, and summarize the persistent symptoms or new-onset clinical manifestations from 4 to 12 weeks after acute COVID. Explore the association between the vaccination status and SARS-CoV-2 neutralizing antibody levels post infection among preschool-aged children. The comprehensive study systematically describes the clinical characteristics of children infected with SARS-CoV-2, providing a foundation for diagnosis and evaluating long-term COVID in pediatric populations. Methods: The study enrolled children who were referred to the Children's Hospital, Capital Institute of Pediatrics, (Beijing, China) from January 10, 2023 to March 31, 2023. Participants were classified as infant and toddlers, preschool, school-age, and adolescent groups. Children or their legal guardians completed survey questionnaires to provide information of previous SARS-CoV-2 infection history, as well as clinical presentation during the acute phase and long-term symptoms from 4 to 12 weeks following infection. Furthermore, serum samples were collected from children with confirmed history of SARS-CoV-2 infection for serological testing of neutralizing antibodies. Results: The study recruited a total of 2,001 children aged 0–17 years who had previously tested positive for SARS-CoV-2 through nucleic acid or antigen testing. Fever emerged as the predominant clinical manifestation in 1,902 (95.1%) individuals with body temperature ranging from 37.3 to 40.0°C. Respiratory symptoms were identified as secondary clinical manifestations, with cough being the most common symptom in 777 (38.8%) children, followed by sore throat (22.1%), nasal congestion (17.8%), and runnning nose (17.2%). Fatigue (21.6%), headache (19.8%) and muscle-joint pain (13.5%) were frequently reported systemic symptoms in children. The proportion of children with symptoms of SARS-CoV-2 infection varied across age groups. 1,100 (55.0%) children experienced persistent symptoms from 4 to 12 weeks post the acute phase of infection. Trouble concentrating (22.1%), cough (22.1%), and fatigue (12.1%) were frequently reported across age groups in the extended period. A limited number of children exhibited cardiovascular symptoms with chest tightness, tachycardia, and chest pain reported by 3.5%, 2.5%, and 1.8% of children, respectively. Among 472 children aged 3–5 years, 208 children had received two doses of SARS-CoV-2 vaccine at least 6 months prior to infection, and no association was found between the incidence of long-term COVID and pre-infection vaccination statuses among the 3–5 years age groups ( χ 2 = 1.136, P = 0.286). Conclusions: In children aged 0–17 years infected with SARS-CoV-2 Omicron variant, fever was the primary clinical manifestation in the acute phase, followed by respiratory symptoms, systemic non-specific and digestive presentations. In particular, respiratory and digestive system symptoms were more frequent in children aged above 6 years. Regarding the long-term symptoms from 4 to 12 weeks post-infection, the most common presentations were concentrating difficulty, cough, and fatigue. The incidence of persistent symptoms of SARS-CoV-2 did not exhibit a significant correlation with vaccination status, which was attributed to the waning efficacy of the vaccine-induced humoral immune response after 6 months.

Innate cell profiles during the acute and convalescent phase of SARS-CoV-2 infection in children

Differences In Clinical Features And Laboratory Results Between Adults And Children With Sars-Cov-2 Infection

Characteristics of innate, humoral and cellular immunity in children with non-severe SARS-CoV-2 infection

Elucidating systemic immune responses to acute and convalescent SARS‐CoV‐2 infection in children and elderly individuals

The Immunological Profile of SARS-CoV-2 Infection in Children Is Linked to Clinical Severity and Age

Tracking the clonal dynamics of SARS-CoV-2-specific T cells in children and adults with mild/asymptomatic COVID-19

Immunological characterization and comparison of children with COVID-19 from their adult counterparts at single-cell resolution

Reduced Inflammatory Responses to SARS-CoV-2 Infection in Children Presenting to Hospital with COVID-19 in China

Age-related Differences in the Nasal Mucosal Immune Response to SARS-CoV-2

Mild Cytokine Elevation, Moderate CD4+ T Cell Response and Abundant Antibody Production in Children with COVID-19

What We Should Know about SARS-CoV-2 Infection in Children

The Effect of Age and Comorbidities: Children vs. Adults in Their Response to SARS-CoV-2 Infection

Primary SARS‐CoV‐2 infection in children and adults results in similar Fc‐mediated antibody effector function patterns

Childhood COVID-19: a Multicentre Retrospective Study

The kinetics and durability of antibody and T-cell responses to SARS-CoV-2 in children

Comparison of Clinical and Para-Clinical Characteristics Between Children and Adults with the Omicron Variant of COVID-19

The mechanisms of milder clinical symptoms of COVID-19 in children compared to adults

Clinical manifestations and long-term symptoms associated with SARS-CoV-2 omicron infection in children aged 0–17 years in Beijing: a single-center study

Age-specific nasal epithelial responses to SARS-CoV-2 infection

Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

High burden of viruses and bacterial pathobionts drives heightened nasal innate immunity in children